A possible role for enzymes in tumour-cell invasion

Medical Hypotheses

Volumn 48, Issue 5, 1997, Pages 443-447

  Van Aswegen, C H ^a   Du Plessis, D J ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIDASE; MATRIX METALLOPROTEINASE; PLASMIN; SIALYLTRANSFERASE; UROKINASE;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL MIGRATION; EXTRACELLULAR MATRIX; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR CELL;

EID: 0030920282     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90044-X     Document Type: Article

References (63)

1. Costanza M E, Li F P, Greene H L, Patterson W B. Cancer prevention and detection. In: Cancer Manual, American Cancer Society Massachusetts Division, Boston Massachusetts 02116: Massachusetts Division Inc. 1982: 1-21.
2. Salomon D S, Perroteau I. Growth factors in cancer and their relationship to oncogenes. Cancer Invest 1986; 4: 43-60.
3. Aznavoorian S, Murphy A N. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368-1378.
4. Darnell J, Lodish H, Baltimore D, eds. Molecular Cell Biology. New York: W H Freeman, 1990: 903-951.
5. Facino R M, Carini M, Aldini G et al. Direct characterization of caffeoyl esters with antihyaluronidase activity in crude extracts from Echinacea angustifolia roots by fast atom bombardment tandem mass spectrometry. Farmaco 1993; 48: 1447-1461.
6. Takahashi K, Stamenkovic I, Cutler M, Saya H, Tanabe K K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 1995; 11: 2223-2232.
7. Jiang W H, Hiscox S, Hallett M B, Scott C, Horrobin D F, Puntis M C A. Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by γ-linolenic acid. Br J Cancer 1995; 71: 744-752.
8. Spieker N, Mareel M, Bruyneel E A, Nederbragt H. E-cadherin expression and in vitro invasion of canine mammary tumor cells. Eur J Cell Biol 1995; 68: 427-436.
9. Jiang W G, Puntis M C A, Hallett M B. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surgery 1994; 81: 1576-1590.
10. Morton R A, Ewing C M, Watkins J J, Isaacs W B. The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J Urol 1995; 13: 364-368.
11. Gessner P, Riedl S, Quentmaier A, Kemmner W. Enhanced activity of CMP-neuAc: Gal beta 1-4G1cNAc: alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett 1993; 75: 143-149.
12. Petrick A T, Meterissian S, Steele G, Thomas P. Desialylation of metastatic human colorectal carcinoma cells facilitates binding to Kupffer cells. Clin Exp Metastasis 1994; 12: 108-116.
13. Kemmer W, Kruck D, Schlag P. Different sialyltransferase activities in human colorectal carcinoma cells from surgical specimens detected by specific glycoprotein and glycolipid acceptors. Clin Exp Metastasis 1994; 12: 245-254.
14. Corfield A P, Clamp J R, Casey A D, Paraskeva C. Characterization of a sialic-acid-rich mucus glycoprotein secreted by a premalignant human colorectal adenoma cell line. Int J Cancer 1990; 46: 1059-1065.
15. Hobarth K, Hofbauer J, Fang-Kircher S. Plasma sialic acid in patients with prostate cancer. Br J Urol 1993; 72: 621-624.
16. Vedralova E, Borovansky J. Evaluation of serum sialic acid fractions as markers for malignant melanoma. Cancer Lett 1994; 78: 171-175.
17. Harvey B E, Toth C A, Wagner H E, Steele G D, Thomas P. Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res 1992; 52: 1775-1779.
18. Shah S, Lance P, Smith T J et al. N-Butyrate reduces the expression of beta-galactoside alpha 2,6-lialyltransferase in Hep G2 cells. J Biol Chem 1992; 267: 10652-10658.
19. Ishii S, Ford R, Thomas P, Nachman A, Steele G Jr, Jessup J M. Cd44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol 1993; 2: 255-264.
20. Tanabe K T, Ellis L M, Saya H. Expression of DC44R1 adhesion molecule in colon carcinomas and metastasis. Lancet 1993; 341: 725-726.
21. Heider K H, Hofmann M, Hors E et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993; 120: 227-233.
22. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
23. Fidler I J. Critical factors in the biology of human cancer metastasis: twenty-eight GHA Clowes memorial award lecture. Cancer Res 1990; 50: 6130-6138.
24. Blood C H, Zetter Bruce R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
25. Schwalke M A, Tzanakakis G N, Vezeridis M P. Effects of prostacyclin on hepatic metastases from human pancreatic cancer in the nude mouse. J Surg Res 1990; 49: 164-167.
26. Zhu D, Cheng C F, Pauli B U. Blocking of lung endothelial cell adhesion molecule-1 (lu-ECAM-1) inhibits murine melanoma lung metastasis. J Clin Invest 1992; 89: 1718-1724.
27. MacNeil S, Wagner M, Kirkham P R et al. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 1993; 3: 67-74.
28. Miyagi E, Yasumitsu H, Hirahara F et al. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995; 86: 568-576.
29. Goretzki L, Schmitt M, Mann K et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 1992; 297: 112-118.
30. Markus G, Takita H, Camiolo S M, Corasanti J G, Evers J L, Hobika G H. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980; 40: 841-848.
31. Mira-y-Lopez R, Reich E, Stolfi R L, Martin D S, Ossowski L. Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma. Cancer Res 1985; 45: 2270-2276.
32. De Bruin P A, Griffioen G, Verspagct H W et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988; 48: 4520-4524.
33. Pereyra-Alfonso S, Haedo A, Bal de Kier Joffe E. Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. Int J Cancer 1988; 42: 59-63.
34. Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen H R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988; 48: 1348-1349.
35. Emmert-Buck M R, Roth M J, Zhuang Z et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumour regions of human colon cancer samples. Am J Pathol 1994; 145: 1285-1290.
36. Gleeson N, Consalves, Bonnar J. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol 1992; 47: 58-61.
37. Garcia Frade L J, Sureda A, Torrado M C, Garcia Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992; 88: 7-10.
38. Fiekens J A, Schmitt M, van Putten W L et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
39. Sier C F, Quax P H, Vloedgraven H J et al. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 1993; 13: 277-288.
40. Stahl A, Mueller B M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-3071.
41. Blanchi E, Cohen R L, Thor A T et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-866.
42. Zucker S. A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Inv 1988; 6: 219-231.
43. Duffy M J, Reilly D, O'Sullivan C, O'Higgins N, Fennelly J J, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-6829.
44. Grondahl-Hansen J, Christensen I J, Rosenquist C et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
45. Rabbani S A, Harakidas P, Davidson D J, Henkin H, Mazar A P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995; 63: 840-845.
46. Higazi A A, Mayer M. Enhanced activity of plasmin and plasminogen activation in the presence of oleic acid. In: Brackman P, Kluft C, eds. Plasminogen activation in fibrinolysis, in tissue remodeling, and in development. Ann N Y Acad Sci 1992; 667: 81-83.
47. Du Toit P J, van Aswegen C H, du Plessis D J. The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells. Prostagland Leukotr Ess Fatty Acids (in press).
48. Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191-217.
49. Thorgeirsson U P. Basement membrane type IV collagen degradation: evidence of the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001.
50. Kusukawa J, Sasaguri Y, Morimatsu M, Kameyama T. Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg 1995; 53: 530-534.
51. Liotta L A, Rao C N, Wewer U M. Biochemical interaction of tumor cells with the basement membrane. Ann Rev Biochem 1986; 55: 1037-1057.
52. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Wakman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994; 70: 506-512.
53. Davies B, Waxman J, Wasan H et al. Levels of matrix metalloproteinases in bladder cancer. Cancer Res 1993; 53: 5365-5369.
54. Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995; 71: 1039-1045.
55. Basset P, Wolf C, Rouyer N, Bellocq J P, Rio M C, Chambon P. Stromelysin 3 in stromal tissue as a control factor in breast cancer behaviour. Cancer 1994; 74: 1045-1049.
56. Johnson S, Johnson F N. Gamma-linolenic acid. Rev Contemp Pharmacotherap 1990; 1: 1-41.
57. Horrobin D F. Essential fatty acids, lipid peroxidation and cancer. In: Horrobin D F, ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Alan Liss, 1990: 351-378.
58. Lokeshwar B L, Selzer M G, Block N L, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissue. Cancer Res 1993; 53: 4493-4498.
59. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990; 269: 93-95.
60. Watanabe S, Hayashi H, Onozaki K, Okuyama H. Effect of dietary alpha-linolenate/linoleate balance on lipopolysaccharide-induced tumor necrosis factor production in mouse macrophages. Life Sci 1991; 48: 2013-2020.
61. Lotz M, Guerne P A. Inter leukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythoid potentiating activity (TIMP-1/EPA). J Biol Chem 1991; 266: 62017-62020.
62. Samad F, Bergtrom G, Amrani D L. Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. Biochim Biophys Acta 1994; 1221: 307-314.
63. Tappia P S, Man W J, Grimble R F. Influence of unsaturated fatty acids on the production of tumour necrosis factor and interleukin-6 by rat peritoneal macrophages. Mol Cell Biochem 1995; 143: 89-98.